Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Wednesday, March 21, 2018 · 437,922,223 Articles · 3+ Million Readers

Update on GSK and BARDA $200 Million Antibiotic Collaboration

Superbugs & Superdrugs 2014

Superbugs & Superdrugs 2014

GSK and BARDA provide unique insights into stimulating new antibiotic research through PPP’s at SMi's 16th annual conference on Superdrugs & Superdrugs

There is a paradigm shift in the way Pharma companies are tackling antimicrobial research. The funding of studies and the stance of the regulatory agencies are changing...”
— Sanofi, R&D TSU Infectious Diseases

LONDON, LONDON, UNITED KINGDOM, February 4, 2014 / -- SMi's Superbugs & Superdrugs conference series has become a focal point for everyone working in the market for infectious diseases. Attending provides a unique forum to engage with KOL’s and leading industry experts active in the field. With now just 4 weeks to go until the 16th annual event, places are now strictly limited. For those who are interested in attending you can still book online at

When the U.S. government signed an antibiotics development deal worth up to $200 million with GlaxoSmithKline to tackle the threats of drug resistance, the collaboration became the first of its kind.

Following on from this, Superdrugs & Superdrugs 2014 will provide unique insights from both GSK and BARDA. Attendees will hear James Anderson, European Partnerships Director from GSK, address the benefits of stimulating antibiotic research through public private partnerships, followed by a keynote address by BARDA Branch Chief, Joseph Larsen. Highlights from the presentation entitled: Working with BARDA, will include,

Overview of BARDA,
The strategic way of solving critical health issues
Current research projects with BARDA
BARDA’s support in new broad spectrum antibiotic research

Click here to view conference agenda and full speaker line-up

Delegates will also be able to join the debate and pose questions to both GSK and BARDA, who will then lead a panel discussion alongside The European Commission, EFPIA and TranScrip Partners on: Considering Different Sources of Funding Antibiotic R&D.

A snap shot of attendees who have already confirmed attendance include:

Anacor Pharmaceuticals, Astellas Pharma Europe, Basilea Pharmaceutica Ltd
Bristol NHS, DSTL Chemical & Biological Sciences, F Hoffmann -La Roche, Ferrer International, Grifols America, Idenix Laboratories, Johnson & Johnson, MedImmune, Melinta Therapeutics, MHRA, NDA Group, Nosopharm, Office for Health Economics, Phico Therapeutics, Procarta Biosystems, Sanofi-Aventis, The Wellcome Trust, Tiber Creek Partners, University of North Texas Health Science Centre
UNTHSC, PreClinical Services, Valoralia plus many more!

For further details on the conference visit

Superdrugs & Superbugs
5th - 6th March 2014
Holiday Inn Regents Park, London UK

Teri Arri
SMi Group Ltd
+44 (0)20 7827 6162
email us here

Powered by EIN Presswire